Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative Losartan Effects on Emphysema Progression Clinical Trial

• Published in: American journal of respiratory and critical care medicine 2022-10, Vol.206 (7), p.838-845
• Main Authors: Wise, Robert A, Holbrook, Janet T, Brown, Robert H, Criner, Gerard J, Dransfield, Mark T, He, Jiaxian, Henderson, Robert J, Kaminsky, David A, Kaner, Robert J, Lazarus, Stephen C, Make, Barry J, McCormack, Meredith C, Neptune, Enid R, Que, Loretta G
• Format: Article
• Language: English
• Subjects: Aged; Angiotensin Receptor Antagonists - therapeutic use; Bronchodilator Agents - therapeutic use; Bronchodilators; Chronic obstructive pulmonary disease; Clinical outcomes; Clinical trials; Disease Progression; Emphysema; Female; Forced Expiratory Volume; Humans; Losartan - therapeutic use; Male; Original; Placebo effect; Pulmonary Disease, Chronic Obstructive - complications; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Emphysema - complications; Pulmonary Emphysema - drug therapy
• ISSN: 1073-449X; 1535-4970; 1535-4970
• DOI: 10.1164/rccm.202201-0206OC

There are no pharmacologic agents that modify emphysema progression in patients with chronic obstructive pulmonary disease (COPD). To evaluate the efficacy of losartan, an angiotensin receptor blocker, to reduce emphysema progression. The trial was a multicenter, randomized, placebo-controlled trial conducted between May 2017 and January 2021. Eligible participants were aged ⩾40 years, had moderate to severe airflow obstruction, ⩾10 pack-years of smoking, mild-moderate emphysema on high-resolution computed tomography, and no medical indication for or intolerance of angiotensin receptor blockers. Treatment with losartan 100 mg daily or matching placebo (1:1) was randomly assigned. The primary outcome was emphysema progression on high-resolution computed tomography over 48 weeks. Secondary outcomes included the St George's Respiratory Questionnaire, the modified Medical Research Council dyspnea scale, the COPD Assessment Test, and the Physical Function-Short Form 20a. A total of 220 participants were enrolled; 58% were men, 19% were African American, and 24% were current smokers. The medians (interquartile ranges) for age were 65 (61-73) years and 48 (36-59) for percent predicted FEV after bronchodilator use. The mean (95% confidence interval) percentage emphysema progression was 1.35% (0.67-2.03) in the losartan group versus 0.66% (0.09-1.23) in the placebo group (  = NS). Losartan did not prevent emphysema progression in people with COPD with mild-moderate emphysema. Clinical trial registered with www.clinicaltrials.gov (NCT02696564).